NI202100002A - Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica - Google Patents
Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoicaInfo
- Publication number
- NI202100002A NI202100002A NI202100002A NI202100002A NI202100002A NI 202100002 A NI202100002 A NI 202100002A NI 202100002 A NI202100002 A NI 202100002A NI 202100002 A NI202100002 A NI 202100002A NI 202100002 A NI202100002 A NI 202100002A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pharmaceutical composition
- diosmin
- chewable tablet
- flavonoic fraction
- flavonoic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica en la forma de un comprimido masticable fuertemente dosificado en diosmina micronizada. Esta composición farmacéutica comprende entre un porcentaje de diosmina micronizada entre el 20% y el 80% de la masa total de la composición farmacéutica. Esta composición farmacéutica se utiliza en el tratamiento de la insuficiencia venosa y de la crisis hemorroidal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1856769A FR3083980B1 (fr) | 2018-07-20 | 2018-07-20 | Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202100002A true NI202100002A (es) | 2021-06-22 |
Family
ID=65243687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202100002A NI202100002A (es) | 2018-07-20 | 2021-01-08 | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3823588B1 (es) |
| KR (1) | KR20210034036A (es) |
| CN (1) | CN112423735A (es) |
| AR (1) | AR117612A1 (es) |
| AU (1) | AU2019306315B2 (es) |
| BR (1) | BR112021000440A2 (es) |
| CA (1) | CA3106495C (es) |
| CL (1) | CL2021000083A1 (es) |
| CO (1) | CO2021000115A2 (es) |
| CR (1) | CR20210023A (es) |
| EA (1) | EA202190269A1 (es) |
| EC (1) | ECSP21001232A (es) |
| FR (1) | FR3083980B1 (es) |
| JO (1) | JOP20210003A1 (es) |
| MA (1) | MA53159A (es) |
| MX (1) | MX2021000763A (es) |
| NI (1) | NI202100002A (es) |
| PE (1) | PE20210929A1 (es) |
| PH (1) | PH12021550037A1 (es) |
| SG (1) | SG11202100181YA (es) |
| TW (1) | TWI831808B (es) |
| WO (1) | WO2020016408A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661610B1 (fr) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | Nouvelle forme lyophilisee de la diosmine et sa preparation. |
| FR2661830B1 (fr) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | Nouvelle compositions pharmaceutiques a base de flavonoside. |
| FR2726469B1 (fr) * | 1994-11-08 | 1996-12-13 | Adir | Composition pharmaceutique pour l'administration orale de flavonoides |
| FR2845597B1 (fr) | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer |
| ITMI20050517A1 (it) | 2005-03-30 | 2006-09-30 | Therapicon Srl | Composizione farmaceutica di una tipica frazione microcristallina di flavonoidi |
| FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/fr active Active
-
2019
- 2019-07-19 EP EP19742363.5A patent/EP3823588B1/fr active Active
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/es unknown
- 2019-07-19 CR CR20210023A patent/CR20210023A/es unknown
- 2019-07-19 TW TW108125532A patent/TWI831808B/zh active
- 2019-07-19 AR ARP190102031A patent/AR117612A1/es unknown
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/es unknown
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/fr unknown
- 2019-07-19 CA CA3106495A patent/CA3106495C/fr active Active
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/ko active Search and Examination
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/zh active Pending
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/pt unknown
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 EA EA202190269A patent/EA202190269A1/ru unknown
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
- 2019-07-19 MA MA053159A patent/MA53159A/fr unknown
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/ar unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/es unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/es unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/es unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202100181YA (en) | 2021-02-25 |
| EA202190269A1 (ru) | 2021-06-15 |
| AR117612A1 (es) | 2021-08-18 |
| AU2019306315B2 (en) | 2023-03-09 |
| CN112423735A (zh) | 2021-02-26 |
| FR3083980A1 (fr) | 2020-01-24 |
| BR112021000440A2 (pt) | 2021-04-06 |
| FR3083980B1 (fr) | 2021-04-16 |
| MX2021000763A (es) | 2021-03-29 |
| CL2021000083A1 (es) | 2021-07-30 |
| ECSP21001232A (es) | 2021-02-26 |
| CA3106495C (fr) | 2023-08-08 |
| TWI831808B (zh) | 2024-02-11 |
| AU2019306315A1 (en) | 2021-02-11 |
| EP3823588B1 (fr) | 2024-10-23 |
| WO2020016408A1 (fr) | 2020-01-23 |
| KR20210034036A (ko) | 2021-03-29 |
| JOP20210003A1 (ar) | 2021-01-10 |
| CR20210023A (es) | 2021-02-22 |
| CA3106495A1 (fr) | 2020-01-23 |
| PH12021550037A1 (en) | 2021-09-27 |
| TW202019439A (zh) | 2020-06-01 |
| EP3823588A1 (fr) | 2021-05-26 |
| MA53159A (fr) | 2021-05-26 |
| CO2021000115A2 (es) | 2021-01-29 |
| PE20210929A1 (es) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057181A1 (es) | Nueva forma de dosificacion de combinacion | |
| PE20230735A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| MX2020009758A (es) | Producto combinado de inhibidor de bcl-2 o inhibidor dual de bcl-2/bcl-xl e inhibidor de btk y uso de este en la prevencion y/o tratamiento de enfermedades. | |
| CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
| PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
| CL2018001686A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026) | |
| NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| PA8809601A1 (es) | Combinación anti-retroviral | |
| GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| AR048587A1 (es) | Composiciones quimicamente estables de 4-hidroxitamoxifeno | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| CL2023003518A1 (es) | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina | |
| PE20211805A1 (es) | Formulaciones de un inhibidor de axl/mer | |
| UY28517A1 (es) | Nueva combinación | |
| CO6280488A2 (es) | Combinacion farmaceutica | |
| NI202100002A (es) | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica | |
| ES2811674R1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| MX2020003786A (es) | Composiciones orales para el tratamiento de reflujo gastroesofagico. | |
| BR112016006244A2 (pt) | métodos de utilização da iga secretora | |
| AR067351A1 (es) | Combinacion de picotamida con nafronil |